From df11dd30baf607b03bcaf64e0cb4678c1f18be80 Mon Sep 17 00:00:00 2001 From: Yehuda_LevS <272607612+yehudalevy-collab@users.noreply.github.com> Date: Fri, 10 Jul 2026 16:29:31 -0600 Subject: [PATCH 1/2] Add plain-language depression trial summary (#464) --- depression_trial_summary.md | 106 ++++++++++++++++++++++++++++++++++++ 1 file changed, 106 insertions(+) create mode 100644 depression_trial_summary.md diff --git a/depression_trial_summary.md b/depression_trial_summary.md new file mode 100644 index 00000000..cd531d49 --- /dev/null +++ b/depression_trial_summary.md @@ -0,0 +1,106 @@ +# Plain-language summary: focused ultrasound in a small depression trial + +## What did the trial test? + +Researchers at the University of Arizona studied whether transcranial focused +ultrasound (tFUS) could be delivered to a brain area involved in depression and +whether participants' symptoms changed during the study. Transcranial means +"through the skull." Focused ultrasound uses sound waves aimed at a specific +location without surgery. + +The study enrolled 20 adults, ages 18 to 50, who were experiencing a major +depressive episode and clinically significant repetitive negative thinking, such +as persistent rumination or worry. Their depression was moderate to severe at +enrollment. Half reported taking medication for anxiety or depression during the +study, and participants were asked not to change their existing medication or +psychotherapy regimens. + +A custom headset held a 128-element ultrasound array against the forehead. Each +session delivered 10 minutes of low-intensity ultrasound to the left anterior +medial prefrontal cortex. This region is a hub in the default mode network, a +set of connected brain regions active during self-focused thought. Participants +received five sessions during the first week. Those who did not meet the study's +early-remission criteria could receive three sessions per week for two more +weeks, for up to 11 sessions in total. + +## What did the researchers measure? + +The researchers assessed participants before treatment, after week 1, and, when +applicable, after week 3. They used: + +- the Beck Depression Inventory-II (BDI-II), a 21-question self-report measure + of depression symptoms; +- the Hamilton Depression Rating Scale (HDRS), a 17-item interview completed by + a clinician; +- the Perseverative Thinking Questionnaire (PTQ), which measures repetitive + negative thinking; and +- the World Health Organization Quality of Life questionnaire, covering + physical, psychological, social, and environmental well-being. + +The study also tracked suicidal thoughts, possible adverse events, sensations +during sessions, and MRI findings that could indicate small brain bleeds. + +## What did the study find? + +At the start of the study, the average BDI-II score was 38.85. The paper's +statistical model estimated that BDI-II scores decreased by 10.9 points for each +step from baseline to week 1 to week 3. Figure 3 in the paper shows that the +largest group-level decrease occurred during the first week, followed by a +smaller decrease through week 3. The paper does not print exact group-average +BDI-II scores for weeks 1 and 3, so they are not estimated here. + +By each participant's final assessment: + +- 12 of 20 participants (60%) had at least a 50% decrease from baseline on the + self-reported BDI-II; +- 9 of 20 (45%) had at least a 50% decrease on the clinician-rated HDRS; and +- 7 of 20 (35%) met the study's remission thresholds on both depression + measures: a BDI-II score below 13 and an HDRS score below 8. + +The average PTQ score also decreased over time. Physical and psychological +quality-of-life scores and satisfaction with the participant's environment +improved, while the change in social satisfaction was not statistically +significant. + +Two participants stopped after week 1. The paper gives different explanations: +the abstract says time constraints, while the Results and Discussion sections +say lack of symptom improvement. It states that neither withdrawal was due to an +adverse event. No serious adverse events were reported. Some participants +described temporary discomfort, including tension or pain that they associated +with headset tightness. Follow-up MRI readings showed no new microhemorrhages. +These safety observations cover only this small group and short study period. + +## What do these results mean—and what do they not mean? + +The results show that delivering this form of focused ultrasound was feasible in +this study and that depression symptoms decreased during the treatment period. +They support further research, particularly a randomized trial that compares +active ultrasound with a sham procedure. + +The study cannot show that ultrasound caused the improvement. It was an +open-label, unblinded study: every participant knew they were receiving the +procedure, and there was no control or sham group. Placebo effects, continued +medication or psychotherapy, natural symptom changes, and other factors could +have contributed. The study included only 20 people, followed outcomes for no +more than three weeks, and enrolled a relatively young, predominantly female +sample. It therefore cannot establish long-term benefit, uncommon risks, or how +well the findings apply to other people with depression. + +The researchers targeted a hub of the default mode network, but this paper did +not report whether the procedure changed that network's activity. That proposed +mechanism remains a hypothesis. The University of Arizona investigator received +an investigator-initiated grant from Openwater, and several coauthors were +Openwater employees during parts of the study. + +These preliminary findings should not be used to replace established clinical +care or to make treatment decisions. + + +> Openwater's platform is intended exclusively for research purposes and is not cleared or approved by the FDA for clinical use. + +## Where can I read more? + +- Schachtner, J. N., et al. (2025). + [Transcranial focused ultrasound targeting the default mode network for the treatment of depression](https://doi.org/10.3389/fpsyt.2025.1451828). + _Frontiers in Psychiatry, 16_, 1451828. +- [ClinicalTrials.gov study record NCT06320028](https://clinicaltrials.gov/study/NCT06320028) From b98f89f7b9adff3ed582dbca448ce5504484b9cf Mon Sep 17 00:00:00 2001 From: Yehuda_LevS <272607612+yehudalevy-collab@users.noreply.github.com> Date: Sat, 11 Jul 2026 21:15:42 -0600 Subject: [PATCH 2/2] docs: refine medication wording and add suicidality safety finding Address review feedback on #464: - The half-of-cohort medication note said 'for anxiety or depression', but Table 1 lists non-antidepressant medications too; the paper's own wording is neutral ('current psychiatric medication use'). - Add the C-SSRS suicidality-monitoring outcome (no imminent-risk ideation; one transient post-week-3 increase the authors attributed to an unrelated personal event), which the safety paragraph had omitted. Co-Authored-By: Claude Opus 4.8 --- depression_trial_summary.md | 12 ++++++++---- 1 file changed, 8 insertions(+), 4 deletions(-) diff --git a/depression_trial_summary.md b/depression_trial_summary.md index cd531d49..bdbd1352 100644 --- a/depression_trial_summary.md +++ b/depression_trial_summary.md @@ -11,9 +11,9 @@ location without surgery. The study enrolled 20 adults, ages 18 to 50, who were experiencing a major depressive episode and clinically significant repetitive negative thinking, such as persistent rumination or worry. Their depression was moderate to severe at -enrollment. Half reported taking medication for anxiety or depression during the -study, and participants were asked not to change their existing medication or -psychotherapy regimens. +enrollment. Half reported currently taking a psychiatric or other prescribed +medication (most commonly an antidepressant), and participants were asked not to +change their existing medication or psychotherapy regimens. A custom headset held a 128-element ultrasound array against the forehead. Each session delivered 10 minutes of low-intensity ultrasound to the left anterior @@ -68,7 +68,11 @@ say lack of symptom improvement. It states that neither withdrawal was due to an adverse event. No serious adverse events were reported. Some participants described temporary discomfort, including tension or pain that they associated with headset tightness. Follow-up MRI readings showed no new microhemorrhages. -These safety observations cover only this small group and short study period. +No participant reported suicidal thoughts posing an imminent risk to themselves. +One participant reported a temporary increase in suicidal thinking at the +assessment after week 3, which the researchers attributed to a personal event (a +relationship breakup) unrelated to the study procedure. These safety +observations cover only this small group and short study period. ## What do these results mean—and what do they not mean?